Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 1
Submit an article Journal homepage
2,435
Views
0
CrossRef citations to date
0
Altmetric
Coronaviruses

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants

Feng Fana Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Xin Zhanga Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Zhiyu Zhanga Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Yuan Dinga Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Limei Wanga Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Xin Xua Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Yaying Panb School of Biological Science and Basic Medicine, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Fang-Yuan Gongb School of Biological Science and Basic Medicine, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Lin Jiangc Shenzhen Qinglan Biotechnology Co. Ltd., Shenzhen, People’s Republic of ChinaView further author information
,
Lingyu Kangc Shenzhen Qinglan Biotechnology Co. Ltd., Shenzhen, People’s Republic of ChinaView further author information
,
Zhuo Had Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, People’s Republic of ChinaView further author information
,
Huijun Lud Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, People’s Republic of ChinaView further author information
,
Jiawang Houa Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Zhihua Koua Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Gan Zhaoa Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaView further author information
,
Bin Wanga Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Xiao-Ming Gaoa Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2202269 | Received 07 Dec 2022, Accepted 07 Apr 2023, Published online: 01 May 2023

Reprints and Permissions

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article in part or whole.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.